Physician profile
Nancy Chung
NPI 1598923542
$8,520.65
in general payments reported to CMS, 2019-2025
26 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.72 · 2021: $1,360 · 2022: $2,193 · 2023: $2,450 · 2024: $2,304 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,931 · Education: $14.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,931.27 |
| Education | $14.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,489.93 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $2,087.43 | 2021-2025 | Skyrizi, Linzess, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $681.26 | 2021-2024 | Entyvio |
| Qol Medical, LLC | $416.39 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $296.55 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $294.46 | 2021-2024 | Stelara, Tremfya |
| Genzyme Corporation | $285.90 | 2023-2025 | |
| Redhill Biopharma INC. | $238.73 | 2021-2024 | Talicia, Movantik, Aemcolo |
| Daiichi Sankyo INC. | $218.07 | 2022-2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $202.70 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $170.08 | 2021-2024 | Linzess |
| Pfizer INC. | $147.84 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $146.19 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $130.11 | 2021 | |
| Merck Sharp & Dohme LLC | $125.70 | 2021-2024 | Dificid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $96.90 | 2023-2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $95.04 | 2023-2024 | Ocaliva |
| Vivus LLC | $87.17 | 2021-2024 | Qsymia |
| Ferring Pharmaceuticals INC. | $79.82 | 2022 | |
| Ardelyx, INC. | $62.19 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $44.73 | 2021-2023 | |
| Laborie Medical Technologies Corp. | $36.96 | 2023 | |
| Pentax of America, INC. | $26.05 | 2024 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Organon LLC | $25.50 | 2023 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $20.14 | 2023 | |
| Celltrion USA INC. | $14.81 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.